Wyeth Selects Tripos for Next-Generation Discovery IT Solution
News Jan 16, 2006
Tripos, Inc. has announced that Wyeth Pharmaceuticals, a division of Wyeth has chosen Tripos discovery informatics technology as the basis for its next-generation discovery IT solution to be used by scientists throughout Wyeth’s worldwide discovery operations.
Under the terms of this agreement, Tripos is expected to receive approximately $5 million in software license and professional services fees over the next 12–18 months, with certain payments contingent upon the successful achievement of project milestones.
Wyeth’s Scientific Workbench, along with a related integrated data repository, will facilitate cross-team collaboration to improve the way Wyeth scientists capture, manage and use key scientific data to efficiently make decisions.
The workbench is based on Tripos’ SMART-IDEA™ technology, the solution Tripos developed in collaboration with Bristol-Myers Squibb Co. (BMY) and then deployed throughout that pharmaceutical company’s U.S. and Canadian research facilities.
Tripos claims that, through the use of SMART-IDEA technology, discovery scientists can quickly combine data from disparate sources and analyze it using an integrated palette of decision-support tools, thus providing a virtual environment in which biologists, chemists and project leaders can view, share and act on important discovery data.
"Despite the many recent advances made in pharmaceutical research, there is still a significant unmet need for access to integrated discovery data necessary for optimal decision-making," said Bryan Koontz, senior vice president and general manager of Discovery Informatics at Tripos.
"SMART-IDEA allows visionary pharmaceutical companies like Wyeth to maximize resources by dismantling data silos, enhancing the flow of discovery data between project teams and providing the analysis environment to enable more-informed strategic decisions."
The analysis and design portion of this project is already underway, and Tripos expects this first phase of the solution to be deployed to Wyeth’s scientists in fall 2006.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE